BEST of the BROKERS

ASHMORE
House broker UBS has upgraded the emerging markets fund manager from “neutral” to “buy” and upped its target price from 400p to 420p following recent share price underperformance and record inflows. The broker sees significant structural opportunities for growth in emerging market assets.

BTG
Deutsche Bank rates the specialist healthcare company as a “buy” with a target price of 400p following a strong pre-close statement from the group, which the broker says should reassure that management plans to build a US speciality business are working.

SHIRE
Nomura has initiated coverage of the pharmaceuticals group with a “buy” rating and a target price of 2300p, expecting the company’s ADHD drugs – which have shown nine per cent annual growth over the past five years – to see it through shorter term uncertainty over its human genetics therapies.